Sorafenib

Adolescent and young adult survivors of kidney cancer appeared at significantly increased risk for left ventricular ejection fraction, according to study results published in Journal of the National Comprehensive Cancer Network.

The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the agents’ manufacturer.

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Tivozanib improved long-term PFS compared with sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results.

The addition of stereotactic body radiation therapy to sorafenib extended OS among patients with advanced hepatocellular carcinoma, results of the randomized phase 3 NRG Oncology/RTOG 1112 trial showed.

Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the outcome of patients with acute myeloid leukemia who received gilterintib with prior midostaurin or sorafenib therapy.

Bristol Myers Squibb in consultation with the FDA voluntarily withdrew the indication for nivolumab as monotherapy for patients with hepatocellular carcinoma previously treated with sorafenib.

Hepatic arterial infusion chemotherapy of FOLFOX regimens demonstrated superior efficacy and OS than sorafenib as first-line treatment of advanced hepatocellular carcinoma with a heavy intrahepatic tumor burden.

There are four scenarios in which patients with HCC and extrahepatic disease (EHD) should be considered for locoregional therapy (LRT) in the form of radioembolization or other options (eg, ablation, external radiotherapy).